Unit:
Κατεύθυνση Κλινικοπαθολογοανατομική θεώρηση των νεοπλασιών του ανθρώπουLibrary of the School of Health Sciences
Author:
Tsakalaki Eleftheria
Supervisors info:
Ανδρέας Χ. Λάζαρης, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Αφροδίτη Νόννη, Αναπληρώτρια Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Ιωάννα Γιαννοπούλου, Ε.ΔΙ.Π, Ιατρική Σχολή, ΕΚΠΑ
Original Title:
Η σημασία του HER2 στο αδενοκαρκίνωμα παχέος εντέρου
Translated title:
The importance of HER2 in colon adenocarcinoma
Summary:
Colon cancer is the third most common cancer in the world and especially in developed countries due to lifestyle. Part of colon cancers, especially those that are KRAS, BRAF wild type overexpress the HER2 receptor. According to studies, this overexpression of HER2 protein or amplification of the HER2 gene, and as a result the activation of the HER2 pathway, acts as a mechanism of resistance to anti-EGFR therapy. This knowledge has led to several clinical trials examining the effectiveness of dual anti HER2 targeted therapy. The results of these studies show that there is a benefit from the use of anti-HER2 therapy in the treatment of HER2 positive colon cancer. Specific studies such as HERACLES – A and MyPathway have shown that a number of patients have benefited from using the combinations of trastuzumab – lapatinib and trastuzumab – pertuzumab respectively. However, data from larger clinical trials are required before HER2 -directed therapy is incorporated into standard treatment paradigms for CRC. Finally, based on the data so far, the role of HER2 as a prognostic indicator remains uncertain.
Main subject category:
Health Sciences
Keywords:
Cancer, Colon cancer, HER2, Anti-HER2 therapy
Number of references:
107
